AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 11 min read$TWST

Leproust Emily M. sold $1.1M of TWST

Leproust Emily M. (Chief Executive Officer) sold 16,470 shares of Twist Bioscience Corp (TWST) at an average of $67.91 ($65.33–$68.61, $1.12M total) across 4 trades on 2026-05-28 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Leproust Emily M.
Published Jun 1, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 28, 2026, 3:50 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$TWST
Bearish
medium confidence
Mentioned
$TWST
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TWSTBearishLow
01

Why it matters

The disclosed sale adds a modest bearish pressure factor for TWST, though the pre‑arranged nature tempers impact.

02

Market read

Insider sale of $1.1M by the CEO may slightly depress TWST price in the short term.

03

What to watch

The 10b5‑1 plan pre‑arranges sales, reducing negative signal strength.

Relevance 5/10Novelty 3/10Timing: post‑market filing today

Background

Form 4 filings disclose insider transactions; a CEO sale is noteworthy for investors monitoring insider sentiment.

Company-level read

Ticker impact

$TWSTBearishMedium confidence
Context

CEO Emily Leproust sold 16,470 shares for $1.12M via a 10b5‑1 plan.

Expected impact

likely slight downward pressure as investors digest the CEO's sale

Evidence & confidence

A $1.1M sale by the chief executive is material for a mid‑cap biotech, but the amount is modest relative to market cap.

Market effects

Sector

May prompt scrutiny of other biotech insider activity but limited sector impact.

Regional

Minimal effect on broader US market.

Global

Low relevance outside Twist Bioscience.

Counterpoint

What could challenge this read

The sale could be a routine liquidity move unrelated to company outlook.

Key entities

  • person
    Emily M. Leproust

    Chief Executive Officer of Twist Bioscience

  • company
    Twist Bioscience Corp

    Biotech company specializing in synthetic DNA manufacturing

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

TWST insider trading history →

Related articles

OCT 5
$TWSTHigh

Twist Bioscience TWST Stock Jumps On AI Drug Discovery Deals

Twist Bioscience (TWST) stock rose 10.19% after announcing AI drug discovery deals with Eli Lilly's TuneLab. The company reported $118.4M in quarterly revenue, a $35.1M net loss, and positive operating cash flow of $1.1M. Analysts have raised price targets, with Guggenheim setting it at $212. TWST is seen as a key player in AI-driven biotech.

timothysykes.com3 min
SEP 24
$TWSTMed

Twist Bioscience Stock Jumps As Lilly AI Deal Fuels Bullish Target Hike

Twist Bioscience (TWST) stock rose 16.21% after announcing a partnership with Eli Lilly's AI drug discovery platform, TuneLab. The company reported Q3 revenue of $118.4M, with a gross margin of 52% but a net loss of $35.1M. Leerink raised its price target to $160, citing the AI-driven opportunity. TWST is trading at a high valuation with a price-to-sales ratio over 25.

timothysykes.com3 min
SEP 24
$TWSTMed

Twist Bioscience Stock Jumps As AI Deals Fuel Bullish Target Hike

Twist Bioscience (TWST) stock rose 8.35% on September 24, 2026, driven by its AI partnership with Eli Lilly's TuneLab platform. The company's stock has seen significant gains recently, trading at $171.74 from $139 over a few weeks. TWST reported quarterly revenue of $118.38M, with a net loss of $35.05M. Leerink raised its price target to $160, citing AI drug discovery opportunities.

timothysykes.com3 min